Cingulate_Logo_400x400_twitter.jpg
Cingulate to Participate in Benzinga All Live Access Event
March 19, 2024 16:45 ET | Cingulate Inc.
KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Attend DCAT Week 2024 in New York City
March 06, 2024 06:45 ET | Cingulate Inc.
KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
February 13, 2024 06:45 ET | Cingulate Inc.
KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Closing of $7.5 Million Public Offering
February 06, 2024 16:15 ET | Cingulate Inc.
KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Pricing of $7.5 Million Public Offering
February 02, 2024 09:15 ET | Cingulate Inc.
KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate_Logo_400x400_twitter.jpg
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
January 29, 2024 08:00 ET | Cingulate Inc.
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
January 29, 2024 06:45 ET | Cingulate Inc.
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Research Nester Logo.jpg
Behavioral Health Market revenue to surpass USD 67 Billion by 2033, says Research Nester
January 22, 2024 05:00 ET | Research Nester
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The global behavioral health market size is projected to expand at ~5% CAGR between 2023 and 2033. The market is expected to garner a revenue of USD 67...
NeuroSigma.png
NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
January 18, 2024 00:21 ET | NeuroSigma, Inc.
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for...
dd-logo.png
UK’s Psychiatrist-Led Diverse Diagnostics Offers Private ADHD Assessment with Free Consultations
January 12, 2024 09:00 ET | Diverse Diagnostics
Glasgow, United Kingdom, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Diverse Diagnostics, a leading psychiatric clinic based in the United Kingdom, announces the launch of its specialised service offering...